Novartis Inks Up To $1.5B Deal For Gyroscope Therapeutics
Swiss pharmaceutical giant Novartis said Wednesday it plans to buy Gyroscope Therapeutics, a U.K.-based gene therapy company focused on eye diseases, for $1.5 billion including contingency payments....To view the full article, register now.
Already a subscriber? Click here to view full article